Assisted enzyme replacement therapy

Patent metadata

Field	Value
Publication number	US-9889182-B2
Application number	US-201013496180-A
Country	US
Kind code	B2
Filing date	Sep 15, 2010
Priority date	Sep 15, 2009
Publication date	Feb 13, 2018
Grant date	Feb 13, 2018

Abstract

Reagents and methods useful for the synthesis of conjugates comprising guanidinylated cyclic acetals are provided. Also provided are methods for increasing the cellular uptake of various therapeutic compounds and treatment modalities using these conjugates.

First claim

What is claimed is:

1. A conjugate comprising a dimeric guanidinoglycoside and an enzyme useful for treating a lysosomal storage disease, the dimeric guanidinoglycoside is covalently bound to the enzyme, wherein the covalent bond is direct or optionally through a linker; and
wherein each guanidinoglycoside of the dimeric guanidinoglycoside independently comprises an aminoglycoside antibiotic in which all of the ammonium groups have been converted into guanidinium groups.

2. The conjugate of claim 1 , wherein the linker comprises an N-hydroxysuccinimide moiety.

3. The conjugate of claim 1 , wherein the enzyme is selected from the group consisting of: α-D-mannosidase; N-aspartyl-β-glucosaminidase; acid lipase; hexosaminidase A; α-galactosidase A; β-galactosidase; ceramidase; fucosidase; β-glucosidase; N-acetylglucosamine-1-phosphotransferase; galactocerebrosidase; arylsulfatase A; N-acetylglucosamine-1-phosphotransferase; α-L-iduronidase; iduronate sulfatase; heparan sulfamidase; N-acetylglucosaminidase; acetyl-CoA: α-glucosaminide acetyltransferase; N-acetylglucosamine 6-sulfatase; N-acetylgalactosamine-6-sulfate sulfatase; N-acetylgalactosamine-4-sulfatase; β-glucuronidase; hyaluronidase; sialidase; sulfatase; sphingomyelinase; acid α-glucosidase; β-mannosidase; cathepsin K; β-hexosaminidase A; β-hexosaminidase B; α-N-acetylgalactosaminidase; sialin; and hexosaminidase A.

4. The conjugate of claim 3 , wherein the enzyme is β-glucosidase or α-iduronidase.

5. The conjugate of claim 1 , wherein the lysosomal storage disease is selected from the group consisting of: Activator Deficiency; Alpha-mannosidosis; Aspartylglucosaminuria; Cholesteryl ester storage disease; Chronic Hexosaminidase A Deficiency; Cystinosis; Danon disease; Fabry disease; Farber disease; Fucosidosis; Galactosialidosis; Gaucher disease; GM1 gangliosidosis; I-Cell disease; Infantile Free Sialic Acid Storage Disease; Juvenile Hexosaminidase A deficiency; Krabbe disease; Metachromatic Leukodystrophy; Mucopolysaccharidoses disorders; Multiple sulfatase deficiency; Niemann-Pick disease; Neuronal Ceroid Lipofuscinoses; Pompe disease; Pycnodysostosis; Sandhoff disease; Schindler disease; Salla disease; Tay-Sachs; and Wolman disease.

6. The conjugate of claim 5 , wherein the Mucopolysaccharidoses disorders are selected from the group consisting of: Pseudo-Hurler polydystrophy; Hurler Syndrome; Scheie syndrome; Hurler-Scheie syndrome; Hunter syndrome; Sanfilippo syndrome type A; Sanfilippo syndrome type B; Sanfilippo syndrome type C; Sanfilippo syndrome type D; Morquio type A; Morquio type B; Maroteaux-Lamy; Sly syndrome; and Natowicz syndrome Hyaluronidase deficiency.

7. The conjugate of claim 5 , wherein the Neuronal Ceroid Lipofuscinoses are selected from the group consisting of: CLN6 disease; Batten-Spielmeyer -Vogt/Juvenile NCL/CLN3 disease; Finnish Variant/Late Infantile CLN5; Jansky-Bielschowsky disease/Late infantile CLN2/TPP1 Disease; Kufs/Adult-onset NCL/CLN4 disease; Northern Epilepsy/variant Late Infantile CLN8; Santavuori-Haltia/Infantile CLN1/PPT disease; and β-mannosidosis.

8. The conjugate of claim 1 , wherein each guanidinoglycoside is independently selected from the group consisting of guanidino-amikacin, guanidino-gentamicin, guanidino-kanamycin, guanidino-neomycin, guanidino-netilmicin, guanidino -paromomycin, guanidino-streptomycin, and guanidino-tobramycin.

9. The conjugate of claim 1 , wherein the conjugate has the following structure:
(GG 2 -linker-enzyme
wherein:
GG is a guanidinoglycoside comprising an aminoglycoside antibiotic in which all of the ammonium groups have been converted into guanidinium groups, where each GG is independently bound to the linker; and
enzyme is an enzyme useful for the treatment of a lysosomal storage disease.

10. The conjugate of claim 9 , wherein the enzyme is β-glucuronidase.

11. The conjugate of claim 9 , wherein the dimeric guanidinoglycoside comprises guanidinylated neomycin.

12. A method for treating a lysosomal storage disease in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a conjugate comprising a dimeric guanidinoglycoside and an enzyme useful for treating a lysosomal storage disease, wherein each guanidinoglycoside of the dimeric guanidinoglycoside independently comprises an aminoglycoside antibiotic in which all of the ammonium groups have been converted into guanidinium groups.

13. A method for increasing the cellular uptake of an enzyme useful for treating a lysosomal storage disease, the method comprising:
a) coupling the enzyme to a dimeric guanidinoglycoside to form a conjugate, wherein each guanidinoglycoside of the dimeric guanidinoglycoside independently comprises an aminoglycoside antibiotic in which all of the ammonium groups have been converted into guanidinium groups; and
b) delivering the conjugate to a cell.

14. A method for increasing the lysosomal uptake of an enzyme useful for treating a lysosomal storage disease, the method comprising:
a) coupling the enzyme to a dimeric guanidinoglycoside to form a conjugate, wherein each guanidinoglycoside of the dimeric guanidinoglycoside independently comprises an aminoglycoside antibiotic.in which all of the ammonium groups have been converted into guanidinium groups; and
b) delivering the conjugate to a lysosome.

15. The conjugate of claim 1 , wherein the conjugate delivers the enzyme to a lysosome within a cell.

16. The conjugate of claim 1 , wherein the conjugate localizes within a lysosome within a cell.

17. The conjugate of claim 1 , wherein the uptake of the conjugate into the lysosome is greater than the uptake of the unconjugated enzyme.

18. The conjugate of claim 9 , wherein the linker comprises an N-hydroxysuccinimide moiety.

19. The conjugate of claim 9 , wherein the linker is covalently bound to the enzyme through a amide bond.

20. The conjugate of claim 1 , wherein each guanidinoglycoside of the dimeric glycoside is the same.

21. The conjugate of claim 1 , wherein each guanidinoglycoside is independently selected from the group consisting of guanidino-neomycin, guanidino -paromomycin, and guanidino-tobramycin.

22. The conjugate of claim 1 , wherein each guanidinoglycoside is guanidino-neomycin.

Assignees

• Esko Jeffrey D
• Tor Yitzhak
• Univ California

Inventors

• Esko Jeffrey D
• Tor Yitzhak

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61K47/549

  Sugars, nucleosides, nucleotides or nucleic acids · CPC title

• A61K47/61

  the organic macromolecular compound being a polysaccharide or a derivative thereof · CPC title

• A61K38/47 Primary

  acting on glycosyl compounds (3.2), e.g. cellulases, lactases · CPC title

• C12Y302/01031

  Beta-glucuronidase (3.2.1.31) · CPC title